We are upgrading the repository! A content freeze is in effect until December 6, 2024. New submissions or changes to existing items will not be allowed during this period. All content already published will remain publicly available for searching and downloading. Updates will be posted in the Website Upgrade 2024 FAQ in the sidebar Help menu. Reach out to escholarship@umassmed.edu with any questions.
The histone deacetylase inhibitor, sodium butyrate, alleviates cognitive deficits in pre-motor stage PD
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Document Type
Journal ArticlePublication Date
2012-06-01Keywords
Histone Deacetylase InhibitorsSodium Oxybate
Parkinson Disease
Nervous System Diseases
Neurology
Neuroscience and Neurobiology
Psychiatry
Psychiatry and Psychology
Metadata
Show full item recordAbstract
Parkinson's disease (PD) patients often times experience impairment in their cognitive abilities early on in the progression of the disease. The reported deficits appear to mainly involve functions that are associated with frontal lobe and frontal-striatal pathways subserving attentional set-shifting, working memory and executive function. The current study explored executive function deficits in a rat model of PD in the pre-motor deficit stage. The rats were lesioned with 12 mug of 6-hydroxydonpamine (6-OHDA) in the striatum in a two step process (10 mug/mul followed by 2 mug/mul) 48 hours apart. Executive function was tested at 3 weeks post-surgery using a rat analogue of Wisconsin card sorting test called the Extra Dimensional/Intra Dimensional (ED/ID) set-shifting task. The results demonstrated that performance by the pre-motor rat model of PD was equivalent to that of the control groups in the simple and the compound discriminations as well as the intra-dimensional set-shifting. However the PD group exhibited attentional set-shifting deficits similar to those observed in PD patients. Additionally, sodium butyrate, a short chain fatty acid derivative and inhibitor of class I and II histone deacetylase (HDACi), was tested as a potential therapeutic agent to mitigate the pre-motor cognitive deficits in PD. The results indicated that the sodium butyrate treatment not only effectively alleviated the set-shifting deficits, but also improved the attentional set formation in the treated rats.Source
Neuropharmacology. 2012 Jun;62(7):2409-12. Epub 2012 Feb 13. Link to article on publisher's siteDOI
10.1016/j.neuropharm.2012.01.026Permanent Link to this Item
http://hdl.handle.net/20.500.14038/46046PubMed ID
22353286Related Resources
Link to Article in PubMedae974a485f413a2113503eed53cd6c53
10.1016/j.neuropharm.2012.01.026